A new highly selective metabotropic excitatory amino acid agonist: 2-amino-4-(3-hydroxy-5-methylisoxazol-4-yl)butyric acid. 1996

H Bräuner-Osborne, and F A Sløk, and N Skjaerbaek, and B Ebert, and N Sekiyama, and S Nakanishi, and P Krogsgaard-Larsen
PharmaBiotec Research Center, Department of Medicinal Chemistry, Royal Danish School of Pharmacy, Copenhagen, Denmark.

The homologous series of acidic amino acids, ranging from aspartic acid (1) to 2-aminosuberic acid (5), and the corresponding series of 3-isoxazolol bioisosteres of these amino acids, ranging from (RS)-2-amino-2-(3-hydroxy-5-methylisoxazol-4-yl)acetic acid (AMAA, 6) to (RS)-2-amino-6-(3-hydroxy-5-methylisoxazol-4-yl)hexanoic acid (10), were tested as ligands for metabotropic excitatory amino acid receptors (mGlu1 alpha, mGlu2, mGlu4a, and mGlu6). Whereas AMAA (6) and (RS)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propinoic acid (AMPA, 7) are potent and highly selective agonists at N-methyl-D-aspartic acid (NMDA) and AMPA receptors, respectively, the higher homologue of AMPA (7), (RS)-2-amino-4-(3-hydroxy-5-methylisoxazol-4-yl)butyric acid (homo-AMPA, 8), is inactive at ionotropic excitatory amino acid receptors. Homo-AMPA (8), which is a 3-isoxazolol bioisostere of 2-aminoadipic acid (3), was, however, shown to be a specific and rather potent agonist at mGlu6, approximately 4 times weaker than the nonselective excitatory amino acid receptor agonist (S)-glutamic acid. 2-Aminoadipic acid (3), which shows a complex excitatory amino acid synaptic pharmacology, was an agonist at mGlu6 as well as mGlu2. AMPA (7) and the higher homologue of homo-AMPA (8), (RS)-2-amino-5-(3-hydroxy-5-methylisoxazol-4-yl)pentanoic acid (9), showed relatively weak agonist effects at mGlu6. It is concluded that homo-AMPA (8) is likely to be a useful tool for studies of the pharmacology and physiological role of mGlu6. We describe a new versatile synthesis of this homologue of AMPA and the synthesis of compound 10.

UI MeSH Term Description Entries
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D000409 Alanine A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM. Abufène,Alanine, L-Isomer,L-Alanine,Alanine, L Isomer,L Alanine,L-Isomer Alanine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D016202 N-Methylaspartate An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA). N-Methyl-D-aspartate,NMDA,N-Methyl-D-aspartic Acid,Acid, N-Methyl-D-aspartic,N Methyl D aspartate,N Methyl D aspartic Acid,N Methylaspartate
D016466 CHO Cells CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells. CHO Cell,Cell, CHO,Cells, CHO
D018094 Receptors, Metabotropic Glutamate Cell surface proteins that bind glutamate and act through G-proteins to influence second messenger systems. Several types of metabotropic glutamate receptors have been cloned. They differ in pharmacology, distribution, and mechanisms of action. Glutamate Receptors, Metabotropic,Metabotropic Glutamate Receptors,Receptors, Glutamate, Metabotropic,Metabotropic Glutamate Receptor,Glutamate Receptor, Metabotropic,Receptor, Metabotropic Glutamate
D018350 alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies. AMPA,AMPA, (+-)-Isomer,AMPA, (R)-Isomer,AMPA, (R)-Isomer, Monohydrobromide,AMPA, (S)-Isomer,AMPA, (S)-Isomer, Monohydrobromide,alpha Amino 3 hydroxy 5 methyl 4 isoxazolepropionic Acid

Related Publications

H Bräuner-Osborne, and F A Sløk, and N Skjaerbaek, and B Ebert, and N Sekiyama, and S Nakanishi, and P Krogsgaard-Larsen
September 2008, Acta pharmaceutica (Zagreb, Croatia),
H Bräuner-Osborne, and F A Sløk, and N Skjaerbaek, and B Ebert, and N Sekiyama, and S Nakanishi, and P Krogsgaard-Larsen
October 2013, Journal of medicinal chemistry,
H Bräuner-Osborne, and F A Sløk, and N Skjaerbaek, and B Ebert, and N Sekiyama, and S Nakanishi, and P Krogsgaard-Larsen
September 2002, Journal of medicinal chemistry,
H Bräuner-Osborne, and F A Sløk, and N Skjaerbaek, and B Ebert, and N Sekiyama, and S Nakanishi, and P Krogsgaard-Larsen
June 2008, Acta crystallographica. Section E, Structure reports online,
H Bräuner-Osborne, and F A Sløk, and N Skjaerbaek, and B Ebert, and N Sekiyama, and S Nakanishi, and P Krogsgaard-Larsen
November 2009, Acta crystallographica. Section E, Structure reports online,
H Bräuner-Osborne, and F A Sløk, and N Skjaerbaek, and B Ebert, and N Sekiyama, and S Nakanishi, and P Krogsgaard-Larsen
May 2003, Journal of medicinal chemistry,
H Bräuner-Osborne, and F A Sløk, and N Skjaerbaek, and B Ebert, and N Sekiyama, and S Nakanishi, and P Krogsgaard-Larsen
September 2005, Acta crystallographica. Section C, Crystal structure communications,
H Bräuner-Osborne, and F A Sløk, and N Skjaerbaek, and B Ebert, and N Sekiyama, and S Nakanishi, and P Krogsgaard-Larsen
June 2004, Farmaco (Societa chimica italiana : 1989),
H Bräuner-Osborne, and F A Sløk, and N Skjaerbaek, and B Ebert, and N Sekiyama, and S Nakanishi, and P Krogsgaard-Larsen
February 2010, Journal of medicinal chemistry,
H Bräuner-Osborne, and F A Sløk, and N Skjaerbaek, and B Ebert, and N Sekiyama, and S Nakanishi, and P Krogsgaard-Larsen
April 1967, The Journal of Nihon University School of Dentistry,
Copied contents to your clipboard!